Advisory OTCs? GSK Discusses “Third Class” Drug Paradigm, But Xenical Not Included
This article was originally published in The Pink Sheet Daily
GSK Consumer Healthcare’s Regnier says firm is discussing pharmacy-only class internally but has yet to take a formal stance on the issue. Any switch of the weight-loss drug orlistat would occur within the existing two-class system, the company says.
You may also be interested in...
Roche weight loss drug adds data from the XENDOS trial showing ability to delay onset of type 2 diabetes in obese patients with impaired glucose tolerance. Change could help Roche increase reimbursement for Xenical.
The firm will restate first quarter and 2004 year-end results due to less-than-expected returns of the anabolic agent.